



ÚOCHB AV
IOCB PRAGUE

Ústav organické chemie a biochemie
Akademie věd České republiky, v. v. i.
Institute of Organic Chemistry and Biochemistry
of the Czech Academy of Sciences

PRESS RELEASE

IOCB Prague and Institute of Physiology have signed license agreement with Novo Nordisk

Prague, August 31, 2017 – Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague) in collaboration with Institute of Physiology of the CAS developed new compounds with positive effects in experimental animal models of obesity and type II diabetes. Compounds were developed in the laboratory of Dr. Lenka Maletínská (IOCB Prague) whose team focused on synthesis and study of modified analogues of endogenous neuropeptides.

Institutes have signed research collaborative and license agreements with major pharmaceutical company Novo Nordisk which will develop and prepare these compounds for preclinical testing on animal models followed by clinical trials if successful.

The Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences / IOCB Prague (www.iocb.cz) is a leading scientific institution in the Czech Republic, recognized internationally. Its primary mission is basic research in the fields of chemical biology and medicinal chemistry, organic and material oriented chemistry, chemistry of natural compounds, biochemistry and molecular biology, physical chemistry, theoretical chemistry, and analytical chemistry. The Institute has a long tradition and expertise in medicinal chemistry and drug development together with the pharma industry. Antivirals discovered by Antonín Holý and developed further by Gilead Sciences revolutionized the treatment of AIDS and hepatitis B and have significantly improved lives of millions of people around the globe.

--- END OF PRESS RELEASE ---

PRESS CONTACT:

Prof. Martin Fusek, martin.fusek@uochb.cas.cz, 220 183 510